Ofatumumab for treating autoimmune nodopathy.

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Autoimmune nodopathy (AN) is a rare neurological disorder requiring effective treatments.
• Current treatment options for AN may have limitations or be ineffective for some patients.

Purpose of the Study:

• To evaluate the efficacy and safety of ofatumumab in treating autoimmune nodopathy (AN).
• To assess ofatumumab as a potential alternative for patients refractory to rituximab.

Main Methods:

• An open-label, prospective, observational study involving eight AN patients.
• Ofatumumab (20 mg) was administered subcutaneously on a specific schedule over 24 weeks.
• Clinical improvement was the primary endpoint, with secondary assessments including neurological scores and biomarkers.

Main Results:

• All eight patients achieved confirmed clinical improvement by Week 24.
• Significant improvements were observed in INCAT scores, MRC sum scores, cI-RODS, grip strength, and nerve conduction studies.
• Reductions in serum neurofilament light chain (sNfL) and anti-paranodal antibodies, along with B-cell depletion, were noted.

Conclusions:

• Ofatumumab therapy at 20 mg subcutaneously over 24 weeks is effective in treating autoimmune nodopathy.
• The treatment demonstrated a favorable safety profile with no serious adverse events reported.
• Ofatumumab presents a convenient, safer, and effective alternative for AN patients, including those who did not respond to rituximab.